Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Noonan Syndrome 5 1Advanced Solid Tumor 1

Interventions

pembrolizumab 166Carboplatin 132Cisplatin 81Paclitaxel 78Gemcitabine 77Pemetrexed 72Bevacizumab 63Docetaxel 54Fluorouracil 49Oxaliplatin 48Dexamethasone 46durvalumab 43atezolizumab 39Leucovorin 39130-nm albumin-bound paclitaxel 39Capecitabine 37Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Prednisone 28Lenalidomide 28enzalutamide 27pomalidomide 25Letrozole 25Irinotecan 25daratumumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Antineoplastic Agents × 30 days × Clear all
NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡